{"transactions":[{"id":4634668,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":34000,"kind":"person","name":"Fox Jonathan C","position":1,"cik":"0001655016","reported_name":"Fox Jonathan C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-03T00:47:07.000Z","date":"2026-10-01","kind":"grant","planned":false,"acquired":true,"shares":308,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25141,"source":{"system":"sec-edgar","filing":"0001655016-26-000006","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000165501626000006/primarydocument.xml","form_type":"4"}},{"id":685542,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22886,"kind":"person","name":"Nofi Michael","position":1,"cik":"0001705477","reported_name":"Nofi Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-17T22:41:33.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":48750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date."}],"balance_after":48750,"derivative":{"exercise_price":43.56,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":48750},"source":{"system":"sec-edgar","filing":"0001705477-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000170547726000002/primarydocument.xml","form_type":"4/A","original_submission_date":"2026-08-14"}},{"id":685541,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-17T22:41:07.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date."}],"balance_after":65000,"derivative":{"exercise_price":43.56,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001644087-26-000006","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000006/primarydocument.xml","form_type":"4/A","original_submission_date":"2026-08-14"}},{"id":685666,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22917,"kind":"person","name":"Russell Alan J","position":1,"cik":"0001853529","reported_name":"Russell Alan J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-17T22:40:43.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date."}],"balance_after":65000,"derivative":{"exercise_price":43.56,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001853529-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853529/000185352926000003/primarydocument.xml","form_type":"4/A","original_submission_date":"2026-08-14"}},{"id":685540,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22884,"kind":"person","name":"MOORE JOHN R","position":1,"cik":"0001191702","reported_name":"MOORE JOHN R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-17T22:40:18.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date."}],"balance_after":65000,"derivative":{"exercise_price":43.56,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001191702-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000119170226000002/primarydocument.xml","form_type":"4/A","original_submission_date":"2026-08-14"}},{"id":685665,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22916,"kind":"person","name":"Derakhshan Behrad","position":1,"cik":"0001853109","reported_name":"Derakhshan Behrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-17T22:39:47.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date."}],"balance_after":100000,"derivative":{"exercise_price":43.56,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001853109-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853109/000185310926000002/primarydocument.xml","form_type":"4/A","original_submission_date":"2026-08-14"}},{"id":686952,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22886,"kind":"person","name":"Nofi Michael","position":1,"cik":"0001705477","reported_name":"Nofi Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-14T20:54:37.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":48750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date."}],"balance_after":48750,"derivative":{"exercise_price":0,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":48750},"source":{"system":"sec-edgar","filing":"0001705477-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000170547726000001/primarydocument.xml","form_type":"4"}},{"id":686951,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22886,"kind":"person","name":"Nofi Michael","position":1,"cik":"0001705477","reported_name":"Nofi Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-08-14T20:54:37.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":24375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted Stock Units (\"RSUs\") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027."}],"balance_after":24375,"derivative":{"exercise_price":0,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":24375},"source":{"system":"sec-edgar","filing":"0001705477-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000170547726000001/primarydocument.xml","form_type":"4"}},{"id":686950,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-14T20:54:16.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date."}],"balance_after":65000,"derivative":{"exercise_price":0,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001644087-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000005/primarydocument.xml","form_type":"4"}},{"id":686949,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Restricted Stock Units","published_at":"2026-08-14T20:54:16.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Restricted Stock Units (\"RSUs\") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027."}],"balance_after":32500,"derivative":{"exercise_price":0,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001644087-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000005/primarydocument.xml","form_type":"4"}},{"id":686948,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Restricted Stock Units","published_at":"2026-08-14T20:54:16.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":false,"shares":7031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Restricted Stock Units (\"RSUs\") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026."}],"balance_after":21094,"derivative":{"exercise_price":0,"expiration_date":"2035-08-12","underlying":"Common Stock","underlying_shares":7031},"source":{"system":"sec-edgar","filing":"0001644087-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000005/primarydocument.xml","form_type":"4"}},{"id":686947,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Restricted Stock Units","published_at":"2026-08-14T20:54:16.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":false,"shares":5781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Restricted Stock Units (\"RSUs\") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025."}],"balance_after":11563,"derivative":{"exercise_price":0,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":5781},"source":{"system":"sec-edgar","filing":"0001644087-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000005/primarydocument.xml","form_type":"4"}},{"id":686946,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-08-14T20:54:16.000Z","date":"2026-08-13","kind":"sale","planned":false,"acquired":false,"shares":2919,"price":43.4065,"value":126703.5735,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"The sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.12 to $43.75, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":8625,"source":{"system":"sec-edgar","filing":"0001644087-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000005/primarydocument.xml","form_type":"4"}},{"id":686945,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-08-14T20:54:16.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":800,"price":44.5175,"value":35614.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.43 to $44.57, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":11544,"source":{"system":"sec-edgar","filing":"0001644087-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000005/primarydocument.xml","form_type":"4"}},{"id":686944,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-08-14T20:54:16.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":104,"price":44.4253,"value":4620.2312,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.42 to $44.43, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":12344,"source":{"system":"sec-edgar","filing":"0001644087-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000005/primarydocument.xml","form_type":"4"}},{"id":686943,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-08-14T20:54:16.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":2779,"price":43.7073,"value":121462.5867,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.21, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":12448,"source":{"system":"sec-edgar","filing":"0001644087-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000005/primarydocument.xml","form_type":"4"}},{"id":686942,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-08-14T20:54:16.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":2839,"price":43.784,"value":124302.776,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.23 to $44.20, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15227,"source":{"system":"sec-edgar","filing":"0001644087-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000005/primarydocument.xml","form_type":"4"}},{"id":686941,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-08-14T20:54:16.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":true,"shares":7031,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":18066,"source":{"system":"sec-edgar","filing":"0001644087-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000005/primarydocument.xml","form_type":"4"}},{"id":686940,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-08-14T20:54:16.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":true,"shares":5781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 887 shares purchased on May 15, 2026 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan."}],"balance_after":11035,"source":{"system":"sec-edgar","filing":"0001644087-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000005/primarydocument.xml","form_type":"4"}},{"id":687036,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22917,"kind":"person","name":"Russell Alan J","position":1,"cik":"0001853529","reported_name":"Russell Alan J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-14T20:53:51.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date."}],"balance_after":65000,"derivative":{"exercise_price":0,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001853529-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1853529/000185352926000002/primarydocument.xml","form_type":"4"}},{"id":687035,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22917,"kind":"person","name":"Russell Alan J","position":1,"cik":"0001853529","reported_name":"Russell Alan J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-08-14T20:53:51.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted Stock Units (\"RSUs\") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027."}],"balance_after":32500,"derivative":{"exercise_price":0,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001853529-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1853529/000185352926000002/primarydocument.xml","form_type":"4"}},{"id":687034,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22917,"kind":"person","name":"Russell Alan J","position":1,"cik":"0001853529","reported_name":"Russell Alan J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-08-14T20:53:51.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":false,"shares":7031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Restricted Stock Units (\"RSUs\") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026."}],"balance_after":21094,"derivative":{"exercise_price":0,"expiration_date":"2035-08-12","underlying":"Common Stock","underlying_shares":7031},"source":{"system":"sec-edgar","filing":"0001853529-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1853529/000185352926000002/primarydocument.xml","form_type":"4"}},{"id":687033,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22917,"kind":"person","name":"Russell Alan J","position":1,"cik":"0001853529","reported_name":"Russell Alan J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-08-14T20:53:51.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":false,"shares":5781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted Stock Units (\"RSUs\") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025."}],"balance_after":11563,"derivative":{"exercise_price":0,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":5781},"source":{"system":"sec-edgar","filing":"0001853529-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1853529/000185352926000002/primarydocument.xml","form_type":"4"}},{"id":687032,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22917,"kind":"person","name":"Russell Alan J","position":1,"cik":"0001853529","reported_name":"Russell Alan J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-14T20:53:51.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":390,"price":44.46,"value":17339.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary sale by the Reporting Person."}],"balance_after":31466,"source":{"system":"sec-edgar","filing":"0001853529-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1853529/000185352926000002/primarydocument.xml","form_type":"4"}},{"id":687031,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22917,"kind":"person","name":"Russell Alan J","position":1,"cik":"0001853529","reported_name":"Russell Alan J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-14T20:53:51.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":2273,"price":43.6759,"value":99275.3207,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.32 to $44.25, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":31856,"source":{"system":"sec-edgar","filing":"0001853529-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853529/000185352926000002/primarydocument.xml","form_type":"4"}},{"id":687030,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22917,"kind":"person","name":"Russell Alan J","position":1,"cik":"0001853529","reported_name":"Russell Alan J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-14T20:53:51.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":3238,"price":43.6775,"value":141427.745,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.33 to $44.26, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":34129,"source":{"system":"sec-edgar","filing":"0001853529-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853529/000185352926000002/primarydocument.xml","form_type":"4"}},{"id":687029,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22917,"kind":"person","name":"Russell Alan J","position":1,"cik":"0001853529","reported_name":"Russell Alan J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-14T20:53:51.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":true,"shares":7031,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":37367,"source":{"system":"sec-edgar","filing":"0001853529-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853529/000185352926000002/primarydocument.xml","form_type":"4"}},{"id":687028,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22917,"kind":"person","name":"Russell Alan J","position":1,"cik":"0001853529","reported_name":"Russell Alan J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-14T20:53:51.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":true,"shares":5781,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":30336,"source":{"system":"sec-edgar","filing":"0001853529-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853529/000185352926000002/primarydocument.xml","form_type":"4"}},{"id":686939,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22884,"kind":"person","name":"MOORE JOHN R","position":1,"cik":"0001191702","reported_name":"MOORE JOHN R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-14T20:53:27.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date."}],"balance_after":65000,"derivative":{"exercise_price":0,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001191702-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000119170226000001/primarydocument.xml","form_type":"4"}},{"id":686938,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22884,"kind":"person","name":"MOORE JOHN R","position":1,"cik":"0001191702","reported_name":"MOORE JOHN R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Units","published_at":"2026-08-14T20:53:27.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Restricted Stock Units (\"RSUs\") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027."}],"balance_after":32500,"derivative":{"exercise_price":0,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001191702-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000119170226000001/primarydocument.xml","form_type":"4"}},{"id":686937,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22884,"kind":"person","name":"MOORE JOHN R","position":1,"cik":"0001191702","reported_name":"MOORE JOHN R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Units","published_at":"2026-08-14T20:53:27.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":false,"shares":6718,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Restricted Stock Units (\"RSUs\") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026."}],"balance_after":20157,"derivative":{"exercise_price":0,"expiration_date":"2035-08-12","underlying":"Common Stock","underlying_shares":6718},"source":{"system":"sec-edgar","filing":"0001191702-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000119170226000001/primarydocument.xml","form_type":"4"}},{"id":686936,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22884,"kind":"person","name":"MOORE JOHN R","position":1,"cik":"0001191702","reported_name":"MOORE JOHN R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Restricted Stock Units","published_at":"2026-08-14T20:53:27.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":false,"shares":5781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted Stock Units (\"RSUs\") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025."}],"balance_after":11563,"derivative":{"exercise_price":0,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":5781},"source":{"system":"sec-edgar","filing":"0001191702-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000119170226000001/primarydocument.xml","form_type":"4"}},{"id":686935,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22884,"kind":"person","name":"MOORE JOHN R","position":1,"cik":"0001191702","reported_name":"MOORE JOHN R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-14T20:53:27.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":2419,"price":43.7985,"value":105948.5715,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.33 to $44.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":17697,"source":{"system":"sec-edgar","filing":"0001191702-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000119170226000001/primarydocument.xml","form_type":"4"}},{"id":686934,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22884,"kind":"person","name":"MOORE JOHN R","position":1,"cik":"0001191702","reported_name":"MOORE JOHN R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-14T20:53:27.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":99,"price":44.5019,"value":4405.6881,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.41 to $44.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":20116,"source":{"system":"sec-edgar","filing":"0001191702-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000119170226000001/primarydocument.xml","form_type":"4"}},{"id":686933,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22884,"kind":"person","name":"MOORE JOHN R","position":1,"cik":"0001191702","reported_name":"MOORE JOHN R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-14T20:53:27.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":59,"price":44.4142,"value":2620.4378,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.40 to $44.42, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":20215,"source":{"system":"sec-edgar","filing":"0001191702-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000119170226000001/primarydocument.xml","form_type":"4"}},{"id":686932,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22884,"kind":"person","name":"MOORE JOHN R","position":1,"cik":"0001191702","reported_name":"MOORE JOHN R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-14T20:53:27.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":2439,"price":43.8081,"value":106847.9559,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.22 to $44.18, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":20274,"source":{"system":"sec-edgar","filing":"0001191702-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000119170226000001/primarydocument.xml","form_type":"4"}},{"id":686931,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22884,"kind":"person","name":"MOORE JOHN R","position":1,"cik":"0001191702","reported_name":"MOORE JOHN R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-14T20:53:27.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":true,"shares":6718,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22713,"source":{"system":"sec-edgar","filing":"0001191702-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000119170226000001/primarydocument.xml","form_type":"4"}},{"id":686930,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22884,"kind":"person","name":"MOORE JOHN R","position":1,"cik":"0001191702","reported_name":"MOORE JOHN R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-14T20:53:27.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":true,"shares":5781,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15995,"source":{"system":"sec-edgar","filing":"0001191702-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000119170226000001/primarydocument.xml","form_type":"4"}},{"id":687025,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22916,"kind":"person","name":"Derakhshan Behrad","position":1,"cik":"0001853109","reported_name":"Derakhshan Behrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-14T20:53:05.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date."}],"balance_after":100000,"derivative":{"exercise_price":0,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001853109-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1853109/000185310926000001/primarydocument.xml","form_type":"4"}},{"id":687024,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22916,"kind":"person","name":"Derakhshan Behrad","position":1,"cik":"0001853109","reported_name":"Derakhshan Behrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2026-08-14T20:53:05.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Restricted Stock Units (\"RSUs\") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027."}],"balance_after":50000,"derivative":{"exercise_price":0,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001853109-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1853109/000185310926000001/primarydocument.xml","form_type":"4"}},{"id":687023,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22916,"kind":"person","name":"Derakhshan Behrad","position":1,"cik":"0001853109","reported_name":"Derakhshan Behrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2026-08-14T20:53:05.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Restricted Stock Units (\"RSUs\") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026."}],"balance_after":22500,"derivative":{"exercise_price":0,"expiration_date":"2035-08-12","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001853109-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1853109/000185310926000001/primarydocument.xml","form_type":"4"}},{"id":687022,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22916,"kind":"person","name":"Derakhshan Behrad","position":1,"cik":"0001853109","reported_name":"Derakhshan Behrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Units","published_at":"2026-08-14T20:53:05.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":false,"shares":5781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted Stock Units (\"RSUs\") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025."}],"balance_after":11563,"derivative":{"exercise_price":0,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":5781},"source":{"system":"sec-edgar","filing":"0001853109-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1853109/000185310926000001/primarydocument.xml","form_type":"4"}},{"id":687021,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22916,"kind":"person","name":"Derakhshan Behrad","position":1,"cik":"0001853109","reported_name":"Derakhshan Behrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-08-14T20:53:05.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":2475,"price":43.6984,"value":108153.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.29 to $44.14, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":31826,"source":{"system":"sec-edgar","filing":"0001853109-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1853109/000185310926000001/primarydocument.xml","form_type":"4"}},{"id":687020,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22916,"kind":"person","name":"Derakhshan Behrad","position":1,"cik":"0001853109","reported_name":"Derakhshan Behrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-08-14T20:53:05.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":150,"price":44.4433,"value":6666.495,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.415 to $44.50, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":34301,"source":{"system":"sec-edgar","filing":"0001853109-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1853109/000185310926000001/primarydocument.xml","form_type":"4"}},{"id":687019,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22916,"kind":"person","name":"Derakhshan Behrad","position":1,"cik":"0001853109","reported_name":"Derakhshan Behrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-08-14T20:53:05.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":304,"price":44.5018,"value":13528.5472,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.47 to $44.54, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":34451,"source":{"system":"sec-edgar","filing":"0001853109-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853109/000185310926000001/primarydocument.xml","form_type":"4"}},{"id":687018,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22916,"kind":"person","name":"Derakhshan Behrad","position":1,"cik":"0001853109","reported_name":"Derakhshan Behrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-08-14T20:53:05.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":2171,"price":43.7934,"value":95075.4714,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.30 to $44.145, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":34755,"source":{"system":"sec-edgar","filing":"0001853109-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853109/000185310926000001/primarydocument.xml","form_type":"4"}},{"id":687017,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22916,"kind":"person","name":"Derakhshan Behrad","position":1,"cik":"0001853109","reported_name":"Derakhshan Behrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-08-14T20:53:05.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":36926,"source":{"system":"sec-edgar","filing":"0001853109-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853109/000185310926000001/primarydocument.xml","form_type":"4"}},{"id":687016,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22916,"kind":"person","name":"Derakhshan Behrad","position":1,"cik":"0001853109","reported_name":"Derakhshan Behrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-08-14T20:53:05.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":true,"shares":5781,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":29426,"source":{"system":"sec-edgar","filing":"0001853109-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853109/000185310926000001/primarydocument.xml","form_type":"4"}},{"id":686929,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":23342,"kind":"person","name":"KOCH KEVIN","position":1,"cik":"0001185829","reported_name":"KOCH KEVIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-14T20:52:31.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date."}],"balance_after":200000,"derivative":{"exercise_price":43.56,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001185829-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000118582926000001/primarydocument.xml","form_type":"4"}},{"id":686928,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":23342,"kind":"person","name":"KOCH KEVIN","position":1,"cik":"0001185829","reported_name":"KOCH KEVIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2026-08-14T20:52:31.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Restricted Stock Units (\"RSUs\") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027."}],"balance_after":100000,"derivative":{"exercise_price":0,"expiration_date":"2036-08-12","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001185829-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000118582926000001/primarydocument.xml","form_type":"4"}},{"id":686927,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":23342,"kind":"person","name":"KOCH KEVIN","position":1,"cik":"0001185829","reported_name":"KOCH KEVIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2026-08-14T20:52:31.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":false,"shares":21875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted Stock Units (\"RSUs\") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026."}],"balance_after":65625,"derivative":{"exercise_price":0,"expiration_date":"2035-08-12","underlying":"Common Stock","underlying_shares":21875},"source":{"system":"sec-edgar","filing":"0001185829-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000118582926000001/primarydocument.xml","form_type":"4"}},{"id":686926,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":23342,"kind":"person","name":"KOCH KEVIN","position":1,"cik":"0001185829","reported_name":"KOCH KEVIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2026-08-14T20:52:31.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":false,"shares":17969,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Restricted Stock Units (\"RSUs\") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025."}],"balance_after":35938,"derivative":{"exercise_price":0,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":17969},"source":{"system":"sec-edgar","filing":"0001185829-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000118582926000001/primarydocument.xml","form_type":"4"}},{"id":686925,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":23342,"kind":"person","name":"KOCH KEVIN","position":1,"cik":"0001185829","reported_name":"KOCH KEVIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-14T20:52:31.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":913,"price":44.33,"value":40473.29,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary sale by the Reporting Person"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.33 to $44.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":52488,"source":{"system":"sec-edgar","filing":"0001185829-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000118582926000001/primarydocument.xml","form_type":"4"}},{"id":686924,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":23342,"kind":"person","name":"KOCH KEVIN","position":1,"cik":"0001185829","reported_name":"KOCH KEVIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-14T20:52:31.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":8276,"price":43.6582,"value":361315.2632,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary sale by the Reporting Person"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":53401,"source":{"system":"sec-edgar","filing":"0001185829-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000118582926000001/primarydocument.xml","form_type":"4"}},{"id":686923,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":23342,"kind":"person","name":"KOCH KEVIN","position":1,"cik":"0001185829","reported_name":"KOCH KEVIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-14T20:52:31.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":8782,"price":43.6408,"value":383253.5056,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary sale by the Reporting Person"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $ 43.26 to $44.10, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":61677,"source":{"system":"sec-edgar","filing":"0001185829-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000118582926000001/primarydocument.xml","form_type":"4"}},{"id":686922,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":23342,"kind":"person","name":"KOCH KEVIN","position":1,"cik":"0001185829","reported_name":"KOCH KEVIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-14T20:52:31.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":true,"shares":21875,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":70459,"source":{"system":"sec-edgar","filing":"0001185829-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000118582926000001/primarydocument.xml","form_type":"4"}},{"id":686921,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":23342,"kind":"person","name":"KOCH KEVIN","position":1,"cik":"0001185829","reported_name":"KOCH KEVIN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-14T20:52:31.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":true,"shares":17969,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":48584,"source":{"system":"sec-edgar","filing":"0001185829-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000118582926000001/primarydocument.xml","form_type":"4"}},{"id":706883,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":29762,"kind":"person","name":"ROOT JONATHAN D","position":1,"cik":"0001225480","reported_name":"ROOT JONATHAN D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:24:59.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":16377,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the Stock Options Granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of shareholders."}],"balance_after":16377,"derivative":{"exercise_price":35.59,"exercise_date":"2027-06-02","expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":16377},"source":{"system":"sec-edgar","filing":"0001710072-26-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000171007226000001/primary_doc.xml","form_type":"4"}},{"id":718264,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22917,"kind":"person","name":"Russell Alan J","position":1,"cik":"0001853529","reported_name":"Russell Alan J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T21:21:17.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":69648,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option vest each month beginning on July 27, 2017, subject to the Reporting Person continuing as a service provider through each vest date."}],"balance_after":1077717,"derivative":{"exercise_price":0.18,"expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":69648},"source":{"system":"sec-edgar","filing":"0001853529-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1853529/000185352926000001/primarydocument.xml","form_type":"4"}},{"id":718263,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22917,"kind":"person","name":"Russell Alan J","position":1,"cik":"0001853529","reported_name":"Russell Alan J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T21:21:17.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":130352,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the option vest each month beginning on September 10, 2018, subject to the Reporting Person continuing as a service provider through each vest date."}],"balance_after":0,"derivative":{"exercise_price":0.45,"expiration_date":"2028-08-30","underlying":"Common Stock","underlying_shares":130352},"source":{"system":"sec-edgar","filing":"0001853529-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1853529/000185352926000001/primarydocument.xml","form_type":"4"}},{"id":718262,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22917,"kind":"person","name":"Russell Alan J","position":1,"cik":"0001853529","reported_name":"Russell Alan J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-02T21:21:17.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":69648,"price":39.4089,"value":2744751.0672,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $40.905, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":24555,"source":{"system":"sec-edgar","filing":"0001853529-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853529/000185352926000001/primarydocument.xml","form_type":"4"}},{"id":718261,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22917,"kind":"person","name":"Russell Alan J","position":1,"cik":"0001853529","reported_name":"Russell Alan J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-02T21:21:17.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":130352,"price":39.406,"value":5136650.912,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $40.81, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":94203,"source":{"system":"sec-edgar","filing":"0001853529-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853529/000185352926000001/primarydocument.xml","form_type":"4"}},{"id":718260,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22917,"kind":"person","name":"Russell Alan J","position":1,"cik":"0001853529","reported_name":"Russell Alan J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-02T21:21:17.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":69648,"price":0.18,"value":12536.64,"ownership":{"direct":true},"balance_after":224555,"source":{"system":"sec-edgar","filing":"0001853529-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853529/000185352926000001/primarydocument.xml","form_type":"4"}},{"id":718259,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22917,"kind":"person","name":"Russell Alan J","position":1,"cik":"0001853529","reported_name":"Russell Alan J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-02T21:21:17.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":130352,"price":0.45,"value":58658.4,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 107 shares purchased on November 15, 2025 and 1,048 shares purchased on May 15, 2026 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan."}],"balance_after":154907,"source":{"system":"sec-edgar","filing":"0001853529-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853529/000185352926000001/primarydocument.xml","form_type":"4"}},{"id":721250,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":34000,"kind":"person","name":"Fox Jonathan C","position":1,"cik":"0001655016","reported_name":"Fox Jonathan C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-01T23:46:25.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":319,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":24833,"source":{"system":"sec-edgar","filing":"0001655016-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000165501626000004/primarydocument.xml","form_type":"4"}},{"id":734154,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37268,"kind":"person","name":"Brege Laura","position":1,"cik":"0001365619","reported_name":"Brege Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T21:14:17.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":16377,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder."}],"balance_after":16377,"derivative":{"exercise_price":35.59,"exercise_date":"2027-06-02","expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":16377},"source":{"system":"sec-edgar","filing":"0001365619-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000136561926000004/primarydocument.xml","form_type":"4"}},{"id":734153,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T20:49:30.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":16377,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder."}],"balance_after":16377,"derivative":{"exercise_price":35.59,"exercise_date":"2027-06-02","expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":16377},"source":{"system":"sec-edgar","filing":"0001357522-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000135752226000001/primarydocument.xml","form_type":"4"}},{"id":734152,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":18365,"kind":"person","name":"Morris Arlene","position":1,"cik":"0001362520","reported_name":"Morris Arlene","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T20:46:58.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":16377,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder."}],"balance_after":16377,"derivative":{"exercise_price":35.59,"exercise_date":"2027-06-02","expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":16377},"source":{"system":"sec-edgar","filing":"0001362520-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000136252026000001/primarydocument.xml","form_type":"4"}},{"id":736217,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-16T22:19:24.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":8188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder."}],"balance_after":8188,"derivative":{"exercise_price":35.59,"exercise_date":"2027-06-02","expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":8188},"source":{"system":"sec-edgar","filing":"0001786966-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000003/primarydocument.xml","form_type":"4"}},{"id":736216,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-16T22:19:24.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":5619,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the Restricted Stock Units granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder."}],"balance_after":5619,"derivative":{"exercise_price":0,"exercise_date":"2027-06-02","expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":5619},"source":{"system":"sec-edgar","filing":"0001786966-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000003/primarydocument.xml","form_type":"4"}},{"id":736214,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":28093,"kind":"person","name":"Martin Christopher Nathan","position":1,"cik":"0002097992","reported_name":"Martin Christopher Nathan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2026-06-16T22:16:53.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":16377,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder."}],"balance_after":16377,"derivative":{"exercise_price":35.59,"exercise_date":"2027-06-02","expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":16377},"source":{"system":"sec-edgar","filing":"0002097992-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000209799226000001/primarydocument.xml","form_type":"4"}},{"id":736213,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":34000,"kind":"person","name":"Fox Jonathan C","position":1,"cik":"0001655016","reported_name":"Fox Jonathan C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-16T22:15:48.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":16377,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder."}],"balance_after":16377,"derivative":{"exercise_price":35.59,"exercise_date":"2027-06-02","expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":16377},"source":{"system":"sec-edgar","filing":"0001655016-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000165501626000003/primarydocument.xml","form_type":"4"}},{"id":791766,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-05T17:15:09.000Z","date":"2026-05-05","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date."}],"balance_after":75000,"derivative":{"exercise_price":7.08,"expiration_date":"2033-08-17","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001644087-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000004/primarydocument.xml","form_type":"4"}},{"id":791765,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-05-05T17:15:09.000Z","date":"2026-05-05","kind":"sale","planned":false,"acquired":false,"shares":50000,"price":38.568,"value":1928400.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $39.96 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4367,"source":{"system":"sec-edgar","filing":"0001644087-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000004/primarydocument.xml","form_type":"4"}},{"id":791764,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-05-05T17:15:09.000Z","date":"2026-05-05","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":7.08,"value":354000.0,"ownership":{"direct":true},"balance_after":54367,"source":{"system":"sec-edgar","filing":"0001644087-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000004/primarydocument.xml","form_type":"4"}},{"id":791763,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-05-05T17:15:09.000Z","date":"2026-05-04","kind":"sale","planned":false,"acquired":false,"shares":5230,"price":31.2931,"value":163662.913,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.72 to $31.66, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4367,"source":{"system":"sec-edgar","filing":"0001644087-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000004/primarydocument.xml","form_type":"4"}},{"id":816470,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":34000,"kind":"person","name":"Fox Jonathan C","position":1,"cik":"0001655016","reported_name":"Fox Jonathan C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-03T18:12:09.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":339,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":24514,"source":{"system":"sec-edgar","filing":"0001655016-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000165501626000002/primarydocument.xml","form_type":"4"}},{"id":819648,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T17:01:22.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":false,"shares":28662,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date."}],"balance_after":125000,"derivative":{"exercise_price":7.08,"expiration_date":"2033-08-17","underlying":"Common Stock","underlying_shares":28662},"source":{"system":"sec-edgar","filing":"0001644087-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000003/primarydocument.xml","form_type":"4"}},{"id":819647,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-04-02T17:01:22.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":28662,"price":32.3109,"value":926095.0158,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.60, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":9597,"source":{"system":"sec-edgar","filing":"0001644087-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000003/primarydocument.xml","form_type":"4"}},{"id":819646,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-04-02T17:01:22.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":true,"shares":28662,"price":7.08,"value":202926.96,"ownership":{"direct":true},"balance_after":38259,"source":{"system":"sec-edgar","filing":"0001644087-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000003/primarydocument.xml","form_type":"4"}},{"id":824169,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-31T23:33:50.000Z","date":"2026-03-31","kind":"exercise","planned":true,"acquired":false,"shares":21338,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date."}],"balance_after":153662,"derivative":{"exercise_price":7.08,"expiration_date":"2033-08-17","underlying":"Common Stock","underlying_shares":21338},"source":{"system":"sec-edgar","filing":"0001644087-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000002/primarydocument.xml","form_type":"4"}},{"id":824168,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-03-31T23:33:50.000Z","date":"2026-03-31","kind":"sale","planned":true,"acquired":false,"shares":21338,"price":32.1168,"value":685308.2784,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.35, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":9597,"source":{"system":"sec-edgar","filing":"0001644087-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000002/primarydocument.xml","form_type":"4"}},{"id":824167,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-03-31T23:33:50.000Z","date":"2026-03-31","kind":"exercise","planned":true,"acquired":true,"shares":21338,"price":7.08,"value":151073.04,"ownership":{"direct":true},"balance_after":30935,"source":{"system":"sec-edgar","filing":"0001644087-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000002/primarydocument.xml","form_type":"4"}},{"id":825294,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-03-30T21:32:38.000Z","date":"2026-03-27","kind":"sale","planned":true,"acquired":false,"shares":6735,"price":30.9778,"value":208635.483,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.49 to $31.68, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":9597,"source":{"system":"sec-edgar","filing":"0001644087-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000001/primarydocument.xml","form_type":"4"}},{"id":825293,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":22885,"kind":"person","name":"Donovan Joanne M.","position":1,"cik":"0001644087","reported_name":"Donovan Joanne M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-03-30T21:32:38.000Z","date":"2026-03-27","kind":"sale","planned":true,"acquired":false,"shares":9623,"price":30.9778,"value":298099.3694,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares sold were acquired through multiple purchases under the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan on May 15, 2022 (1,392 shares), November 15, 2022 (1,406 shares), May 15, 2023 (1,451 shares), November 15, 2023 (1,751 shares), May 15, 2024 (1,803 shares), and November 15, 2024 (1,820 shares)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.49 to $31.68, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 594 shares purchased on November 17,2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan."}],"balance_after":16332,"source":{"system":"sec-edgar","filing":"0001644087-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000164408726000001/primarydocument.xml","form_type":"4"}},{"id":932333,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":false,"shares":13690,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.39,"exercise_date":"2021-03-04","expiration_date":"2028-04-26","underlying":"Common Stock","underlying_shares":13690},"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932332,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":false,"shares":17236,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.64,"exercise_date":"2023-10-16","expiration_date":"2029-11-14","underlying":"Common Stock","underlying_shares":17236},"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932331,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":false,"shares":7605,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.71,"exercise_date":"2024-09-02","expiration_date":"2030-09-01","underlying":"Common Stock","underlying_shares":7605},"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932330,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":false,"shares":66477,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.93,"exercise_date":"2024-02-03","expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":66477},"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932329,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":false,"shares":10463,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.93,"exercise_date":"2024-12-03","expiration_date":"2030-12-15","underlying":"Common Stock","underlying_shares":10463},"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932328,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"sale","planned":true,"acquired":false,"shares":66477,"price":29.44,"value":1957082.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":19820,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932327,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"sale","planned":true,"acquired":false,"shares":10463,"price":29.44,"value":308030.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":86297,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932326,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"sale","planned":true,"acquired":false,"shares":7605,"price":29.44,"value":223891.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":96760,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932325,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"sale","planned":true,"acquired":false,"shares":17236,"price":29.44,"value":507427.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":104365,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932324,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"sale","planned":true,"acquired":false,"shares":13690,"price":29.44,"value":403033.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":121601,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932323,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":true,"shares":7605,"price":0.71,"value":5399.55,"ownership":{"direct":true},"balance_after":135291,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932322,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":true,"shares":66477,"price":1.93,"value":128300.61,"ownership":{"direct":true},"balance_after":127686,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932321,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":true,"shares":10463,"price":1.93,"value":20193.59,"ownership":{"direct":true},"balance_after":61209,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932320,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":true,"shares":17236,"price":0.64,"value":11031.04,"ownership":{"direct":true},"balance_after":50746,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}},{"id":932319,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":37696,"kind":"person","name":"Edris Badreddin","position":1,"cik":"0001786966","reported_name":"Edris Badreddin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-23T18:34:18.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":true,"shares":13690,"price":0.39,"value":5339.1,"ownership":{"direct":true},"balance_after":33510,"source":{"system":"sec-edgar","filing":"0001786966-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000178696626000001/primarydocument.xml","form_type":"4"}}],"next_cursor":"2026-01-23T18:34:18.000000Z,932319"}